

**Supplemental Figure 1.** Parameters from TITAN and HERCULES utilized in cost effectiveness modeling including day of therapeutic plasma exchange, length of stay and percentage of patients who received rituximab. Abbreviations: TPE, therapeutic plasma exchange; LOS, length of stay; ICU, intensive care unit; SOC, standard of care arm. \*LOS parameter from HERCULES was used to fill in missing LOS data in TITAN.

Parameter	TITAN		HERCULES	
	<i>Caplacizumab</i>	SOC	<i>Caplacizumab</i>	SOC
TPE, days	7.7	11.7	5.8	9.4
LOS, days (ICU/total)*	3.4/9.9*	9.7/14.4*	3.4/9.9	9.7/14.4
Rituximab, number of patients (percentage)	2/36 (5.6%)	9/39 (23.1%)	28/72 (38.9%)	35/73 (47.9%)